Last reviewed · How we verify
CC-93538
CC-93538 is a cereblon E3 ligase modulator (CELMoD) that degrades Ikaros and Ikzf3 proteins to enhance T-cell proliferation and anti-tumor immunity.
CC-93538 is a cereblon E3 ligase modulator (CELMoD) that degrades Ikaros and Ikzf3 proteins to enhance T-cell proliferation and anti-tumor immunity. Used for Multiple myeloma, Lymphoma.
At a glance
| Generic name | CC-93538 |
|---|---|
| Also known as | Cendakimab, BMS-986355, RPC4064, cendakimab, RPC4046 |
| Sponsor | Celgene |
| Drug class | Cereblon E3 ligase modulator (CELMoD) |
| Target | Cereblon (CRBN); Ikaros (IKZF1); Ikzf3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a next-generation cereblon ligand, CC-93538 binds cereblon and recruits Ikaros and Ikzf3 for proteasomal degradation, which enhances T-cell activation and proliferation while reducing immunosuppressive signaling. This mechanism differs from earlier IMiDs by providing more selective protein degradation with potentially improved tolerability. The drug is designed to enhance both innate and adaptive immune responses against cancer.
Approved indications
- Multiple myeloma
- Lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Diarrhea
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis (PHASE3)
- Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis (PHASE3)
- A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab (PHASE1)
- A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants (PHASE1)
- A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants (PHASE1)
- Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |